SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness

被引：10

作者：

Cavallari, Ilaria ^{[1
]}

Maddaloni, Ernesto ^{[2
]}

Nusca, Annunziata ^{[1
]}

Tuccinardi, Dario ^{[3
]}

Buzzetti, Raffaella ^{[2
]}

Pozzilli, Paolo ^{[3
]}

Grigioni, Francesco ^{[1
]}

机构：

[1] Campus Bio Medico Univ Rome, Dept Cardiovasc Sci, Via Alvaro Portillo 21, I-00128 Rome, Italy

[2] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy

[3] Campus Bio Medico Univ Rome, Unit Endocrinol & Diabet, Rome, Italy

来源：

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 2022年 / 22卷 / 03期

关键词：

LEFT-VENTRICULAR DYSFUNCTION; CARDIAC-INSUFFICIENCY BISOPROLOL; MYOCARDIAL-INFARCTION; SYSTOLIC DYSFUNCTION; ESC GUIDELINES; MORTALITY; SURVIVAL; ENALAPRIL; MORBIDITY; HEALTH;

D O I：

10.1007/s40256-021-00508-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure (HF) represents a major global health and economic burden with still unacceptably high morbidity and mortality rates. In recent decades, novel therapeutic opportunities with a significant impact on HF outcomes have been introduced in addition to angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and mineralocorticoid receptor antagonists. These include drugs such as ivabradine, sacubitril-valsartan, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. The availability of an extremely large pharmacological armamentarium to face this chronic global disease highlights the importance of assessing cost effectiveness to promote sustainable healthcare. In light of the recent approval of SGLT-2 inhibitors for the treatment of HF with reduced ejection fraction, including in individuals without type 2 diabetes mellitus, the aim of this review was to provide an updated comparative evaluation of the efficacy and cost effectiveness of different pharmacological treatments for the prevention (stage A) and treatment of asymptomatic (stage B) and symptomatic (stages C-D) left ventricular dysfunction.

引用

页码：263 / 270

页数：8

共 54 条

[1] Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction - a meta-analysis [J].

Abdulla, J ;

Pogue, J ;

Abildstrom, SZ ;

Kober, L ;

Christensen, E ;

Pfeffer, MA ;

Yusuf, S ;

Torp-Pedersen, C .

EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (01) :90-96

[2] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[3] Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Khan, Muhammad Shahzeb ;

Marx, Nikolaus ;

Lam, Carolyn S. P. ;

Schnaidt, Sven ;

Ofstad, Anne Pernille ;

Brueckmann, Martina ;

Jamal, Waheed ;

Bocchi, Edimar A. ;

Ponikowski, Piotr ;

Perrone, Sergio, V ;

Januzzi, James L. ;

Verma, Subodh ;

Boehm, Michael ;

Ferreira, Joao Pedro ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

CIRCULATION, 2021, 143 (04) :337-349

[4]

Cosentino Francesco, 2020, Eur Heart J, V41, P255, DOI [10.1093/eurheartj/ehz828, 10.1093/eurheartj/ehz486]

[5] Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis [J].

Arbel, Ronen ;

Aboalhasan, Enis ;

Hammerman, Ariel ;

Azuri, Joseph .

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (15) :1665-1669

[6] Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis [J].

Arbel, Ronen ;

Aboalhasan, Enis ;

Hammerman, Ariel ;

Azuri, Joseph .

CLINICAL DRUG INVESTIGATION, 2020, 40 (07) :665-669

[7] Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study [J].

Boehm, Michael ;

Borer, Jeffrey ;

Ford, Ian ;

Gonzalez-Juanatey, Jose R. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Reil, Jan-Christian ;

Swedberg, Karl ;

Tavazzi, Luigi .

CLINICAL RESEARCH IN CARDIOLOGY, 2013, 102 (01) :11-22

[8]

CAVALLARI I, 2020, EUR J PREV CARDIOL

[9] The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments [J].

Cavallari, Ilaria ;

Maddaloni, Ernesto ;

Pieralice, Silvia ;

Mule, Maria Tea ;

Buzzetti, Raffaella ;

Ussia, Gian Paolo ;

Pozzilli, Paolo ;

Grigioni, Francesco .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09) :E3075-E3089

[10] Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand [J].

Cavallari, Ilaria ;

Maddaloni, Ernesto .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (04)

← 1 2 3 4 5 6 →